Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Becomes CRM Player Overnight By Completing St. Jude Deal

Executive Summary

Abbott Laboratories has finalized its $25b takeover of St. Jude Medical, first announced in April, making Abbott a major player in almost every corner of the $30bn cardiovascular device market.

You may also be interested in...



Deepak Nath Leaves Siemens To Become Smith & Nephew's New CEO

Deepak Nath will take over as Smith & Nephew’s new CEO on 1 April, joining the orthopedics and wound care company after four years as president of Siemens Healthineers’ diagnostics business. Smith & Nephew’s current CEO Roland Diggelmann is stepping down by mutual agreement.

New Heartache For Abbott Implantable Cardiac Devices After Manufacturing Flaw Discovered

US regulators have notified the public about a recall of certain Abbott Ellipse implantable cardioverter defibrillators that are prone to electrical shorting due a manufacturing flaw. While the number of devices so far in the US is very small, the recall highlights continued issues with the ICDs since Abbott acquired them from St. Jude almost three years ago.

Robert Ford Steps Up At Abbott Labs

The company's device business chief is expanding his portfolio as Abbott's new president and chief operating officer, leading to some speculation that he is being positioned to be the next CEO.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT104276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel